Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM2SQBF)

• Drug Name: 225Ac-labelled aCD33 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Acute myeloid leukaemia	2A60	Phase 1	[1]

• Cross-matching ID: TTD Drug ID: DM2SQBF

Molecule-Related Drug Atlas

Drug(s) Targeting Myeloid cell surface antigen CD33 (CD33)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Gemtuzumab ozogamicin	DMJ2O7B	Acute myeloid leukaemia	2A60	Approved	[3]
Vadastuximab talirine	DM9LH10	Acute myeloid leukaemia	2A60	Phase 3	[4]
Actimab-A	DMKBIPR	Acute myeloid leukaemia	2A60	Phase 2	[4]
BI-836858	DMUVMY9	Myelodysplastic syndrome	2A37	Phase 2	[5]
Actimab-MDS	DMP8EEX	Myelodysplastic syndrome	2A37	Phase 2	[6]
GTB-3550	DMK2RIB	Acute myelogenous leukaemia	2A41	Phase 1/2	[7]
SGN-CD33A	DMRC7PI	Acute myeloid leukaemia	2A60	Phase 1/2	[8]
CART33 cells	DM81JIT	Myeloid leukaemia	2B33.1	Phase 1/2	[9]
CD33-specific gene-engineered T cells	DMM35D2	Acute myeloid leukaemia	2A60	Phase 1/2	[10]
Anti-CD33 CAR-T cells	DM9NPF6	Myeloid leukaemia	2B33.1	Phase 1/2	[11]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Myeloid cell surface antigen CD33 (CD33)	TTJVYO3	CD33_HUMAN	Not Available	[2]

References

• [1] ClinicalTrials.gov (NCT03705858) Actinium-225-Lintuzumab in Patients With Acute Myeloid Leukemia. U.S. National Institutes of Health.
• [2] Radiopharmaceutical therapy in cancer: clinical advances and challenges. Nat Rev Drug Discov. 2020 Sep;19(9):589-608.
• [3] Targeted treatment of acute myeloid leukemia in older adults: role of gemtuzumab ozogamicin. Clin Interv Aging. 2009;4:197-205.
• [4] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [5] The past and future of CD33 as therapeutic target in acute myeloid leukemia. Blood Rev. 2014 Jul;28(4):143-53.
• [6] Clinical pipeline report, company report or official report of Actinium Pharmaceuticals
• [7] Clinical pipeline report, company report or official report of GT Biopharma.
• [8] SGN-CD33A: a novel CD33-targeting antibody-drug conjugate using a pyrrolobenzodiazepine dimer is active in models of drug-resistant AML. Blood. 2013 Aug 22;122(8):1455-63.
• [9] ClinicalTrials.gov (NCT01864902) Treatment of Relapsed and/or Chemotherapy Refractory CD33 Positive Acute Myeloid Leukemia by CART-33
• [10] ClinicalTrials.gov (NCT03222674) Multi-CAR T Cell Therapy for Acute Myeloid Leukemia
• [11] ClinicalTrials.gov (NCT03638206) Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies